2qoh: Difference between revisions

Revision as of 04:26, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2qoh.png

Template:STRUCTURE 2qoh

Crystal Structure of Abl kinase bound with PPY-ACrystal Structure of Abl kinase bound with PPY-A

Template:ABSTRACT PUBMED 17718712

About this StructureAbout this Structure

2QOH is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.

ReferenceReference

Crystal structure of the T315I mutant of AbI kinase., Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X, Chem Biol Drug Des. 2007 Sep;70(3):171-81. PMID:17718712

Page seeded by OCA on Tue Jul 29 04:26:11 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2qoh.jpg|left|200px]]
+{{Seed}}
+[[Image:2qoh.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2qoh|  PDB=2qoh  |  SCENE=  }}
-'''Crystal Structure of Abl kinase bound with PPY-A'''
+===Crystal Structure of Abl kinase bound with PPY-A===
-==Overview==
+<!--
-Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-AbI. However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain. Second generation Bcr-AbI inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I). In this study, we present the crystal structure of the kinase domain of the c-AbI T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A. The side chain of Ile315 is accommodated in the AbI T315I mutant structure without large conformational changes proximal to the site of mutation. In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gatekeeper residue. This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be critical for its ability to override the T315I mutation. The data presented here may provide structural guidance for the design of clinically useful inhibitors of Bcr-AbI T315I.
+The line below this paragraph, {{ABSTRACT_PUBMED_17718712}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 17718712 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_17718712}}
 ==About this Structure==
@@ Line 30: / Line 34: @@
 [[Category: Kinase]]
 [[Category: Transferase]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 15:18:50 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 04:26:11 2008''